Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 70.14
OCLS's Cash to Debt is ranked higher than
82% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. OCLS: 70.14 )
OCLS' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 70.14

Equity to Asset 0.35
OCLS's Equity to Asset is ranked higher than
50% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. OCLS: 0.35 )
OCLS' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.69
Current: 0.35

-0.21
0.69
F-Score: 3
Z-Score: -17.99
M-Score: -0.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -21.84
OCLS's Operating margin (%) is ranked higher than
54% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. OCLS: -21.84 )
OCLS' s 10-Year Operating margin (%) Range
Min: -1202.95   Max: -7.35
Current: -21.84

-1202.95
-7.35
Net-margin (%) -35.15
OCLS's Net-margin (%) is ranked higher than
53% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. OCLS: -35.15 )
OCLS' s 10-Year Net-margin (%) Range
Min: -1219.03   Max: -8.35
Current: -35.15

-1219.03
-8.35
ROE (%) -133.08
OCLS's ROE (%) is ranked lower than
54% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. OCLS: -133.08 )
OCLS' s 10-Year ROE (%) Range
Min: -778.14   Max: -17.77
Current: -133.08

-778.14
-17.77
ROA (%) -43.22
OCLS's ROA (%) is ranked lower than
51% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. OCLS: -43.22 )
OCLS' s 10-Year ROA (%) Range
Min: -324.14   Max: -9.9
Current: -43.22

-324.14
-9.9
ROC (Joel Greenblatt) (%) -421.75
OCLS's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. OCLS: -421.75 )
OCLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1208.59   Max: -421.75
Current: -421.75

-1208.59
-421.75
Revenue Growth (%) 11.40
OCLS's Revenue Growth (%) is ranked higher than
84% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. OCLS: 11.40 )
OCLS' s 10-Year Revenue Growth (%) Range
Min: -27.3   Max: 53.6
Current: 11.4

-27.3
53.6
EBITDA Growth (%) -29.50
OCLS's EBITDA Growth (%) is ranked higher than
51% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. OCLS: -29.50 )
OCLS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 372
Current: -29.5

0
372
EPS Growth (%) -19.70
OCLS's EPS Growth (%) is ranked higher than
58% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. OCLS: -19.70 )
OCLS' s 10-Year EPS Growth (%) Range
Min: -54.1   Max: 356.8
Current: -19.7

-54.1
356.8
» OCLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OCLS Guru Trades in

Q2 2012

OCLS Guru Trades in Q2 2012

Jim Simons 12,500 sh (+21.36%)
» More
Q3 2012

OCLS Guru Trades in Q3 2012

Jim Simons 10,200 sh (-18.4%)
» More
Q4 2012

OCLS Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OCLS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.60
OCLS's P/B is ranked lower than
67% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. OCLS: 6.60 )
OCLS' s 10-Year P/B Range
Min: 1.44   Max: 264.25
Current: 6.6

1.44
264.25
P/S 1.50
OCLS's P/S is ranked higher than
78% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. OCLS: 1.50 )
OCLS' s 10-Year P/S Range
Min: 0.89   Max: 18.2
Current: 1.5

0.89
18.2
EV-to-EBIT 100.00
OCLS's EV-to-EBIT is ranked lower than
72% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. OCLS: 100.00 )
OCLS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 100

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.50
OCLS's Price/Tangible Book is ranked lower than
62% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. OCLS: 6.50 )
OCLS' s 10-Year Price/Tangible Book Range
Min: 3.57   Max: 183.75
Current: 6.5

3.57
183.75
Price/Median PS Value 0.30
OCLS's Price/Median PS Value is ranked higher than
99% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. OCLS: 0.30 )
OCLS' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 3.57
Current: 0.3

0.2
3.57
Forward Rate of Return (Yacktman) -135.36
OCLS's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. OCLS: -135.36 )
OCLS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.1   Max: 75.4
Current: -135.36

-3.1
75.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:O8Z1.Germany
Oculus Innovative Sciences, Inc. was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide